Oral Tamoxifen and Abemaciclib in Postoperative Therapy for Male Breast Cancer: A Case Report

Kei Ishii; Masae Torii; Hiroshi Yoshibayashi; Yoshiaki Matsumoto; Yasuo Matsutani

doi:10.12659/AJCR.949005

26 October 2025 : Case report Japan

Oral Tamoxifen and Abemaciclib in Postoperative Therapy for Male Breast Cancer: A Case Report

Unusual setting of medical care, Rare disease

Kei Ishii

^{ABCDEFG 1,2*}, Masae Torii^{D 2}, Hiroshi Yoshibayashi^{C 3}, Yoshiaki Matsumoto

^{B 2}, Yasuo Matsutani^{D 2}

DOI: 10.12659/AJCR.949005

Am J Case Rep 2025; 26:e949005

Authors information Article notes Copyright and License information

Introduction Case Report Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 4 Changes in creatinine, cystatin C, and abemaciclib doses after abemaciclib administration. Due to adverse events, the dose of abemaciclib was gradually reduced.

Back to the Article

Oral Tamoxifen and Abemaciclib in Postoperative Therapy for Male Breast Cancer: A Case Report

Your Privacy